Clinical trials: Pulmonary Artery Hypertension
High Altitude Effects, High Altitude
Assessment of Heart Rate Variability HRV During Descent DE From 2850m to Sea Level and During Re-ascent A From Sea Level to 2850m in Patients With Pulmonary Arterial Hypertension PAH
To study the effect of relocation from high altitude (Quito Ecuador: 2850m) to sea level and re-ascent from sea level to 2850m on heart rate variability and other hemodynamic parameters in patients with pulmonary arterial…
- Conditions
- High Altitude Effects, High Altitude, Pulmonary Vascular Disease, Pulmonary Arterial Hypertension (PAH)
- Trial name
- NCT07801859
- Testing
- Descent and re-ascent (2850m, sea level)
- Where
- Switzerland
- Volunteers
- 20 people
- Sponsor
- Silvia Ulrich Somaini
Heart Failure, Diastolic, Pulmonary Hypertension
Sildenafil in HFpEF (Heart Failure With Preserved Ejection Fraction) and PH
Aim of the study is to investigate whether Sildenafil treatment results in a reduction of pulmonary artery pressure without decrease of cardiac output (CO) and in improvement of exercise capacity in patients with heart failure…
- Trial name
- NCT01726049
- Testing
- Sildenafil
- Where
- Netherlands
- Volunteers
- 52 people
- Sponsor
- University Medical Center Groningen
Pulmonary Hypertension
Efficacy and Safety of Bosentan in Sickle Cell Disease (SCD) Patients With Pulmonary Arterial Hypertension (PAH)
The study will assess the effect of bosentan on pulmonary vascular resistance and exercise capacity in sickle cell disease (SCD) patients diagnosed with pulmonary arterial hypertension.
- Trial name
- NCT00310830
- Testing
- Bosentan
- Volunteers
- 14 people
- Sponsor
- Actelion
Lung Hypoxia, Pulmonary Arterial Hypertension
Iron Status and Hypoxic Pulmonary Vascular Responses
On exposure to hypoxia (low oxygen) the normal response is for pulmonary arterial systolic blood pressure (PASP, blood pressure through the lungs) to increase.
- Conditions
- Lung Hypoxia, Pulmonary Arterial Hypertension, Iron Deficiency
- Trial name
- NCT01847352
- Testing
- Intravenous administration of ferric carboxymaltose, Subacute hypoxic exposures
- Where
- United Kingdom
- Volunteers
- 31 people, healthy volunteers welcome
- Sponsor
- University of Oxford
Pulmonary Hypertension, Mitral Regurgitation
Effect of Brief Nebulization of Milrinone on Pulmonary Arterial Pressure Before Cardiopulmonary Bypass on Mitral Valve Surgery Patients
Our main hypothesis is that inhalation of milrinone can reduce the elevated pulmonary arterial pressure due to severe mitral valve regurgitation without compromising systemic hemodynamics.
- Trial name
- NCT01621971
- Testing
- inhaled milrinone, intravenous milrinone
- Where
- South Korea
- Volunteers
- 20 people
- Sponsor
- Konkuk University Medical Center
Pulmonary Arterial Hypertension
Single Ascending Dose Study for Evaluation of Safety, Tolerability and Pharmacokinetics of L606
The primary objective of this study is to evaluate the Pharmacokinetics, Safety and Tolerability of L606 (Liposomal Treprostinil) Inhalation Solution in Single Ascending Dose study design in healthy volunteers.
- Trial name
- NCT04041648
- Testing
- L606 (Liposomal Treprostinil) Inhalation Solution 51ug, L606 Inhalation System
- Where
- United States
- Volunteers
- 52 people, healthy volunteers welcome
- Sponsor
- Pharmosa Biopharm Inc.
Hypertension, Pulmonary
Evaluation of Inhaled Iloprost Effects Using the Breelib Nebulizer, on Clinical Outcomes and Physical Activity of Patients With Advanced Pulmonary Arterial Hypertension
The main aim of the observational VENTASTEP study was to investigate the association between changes in clinical outcome measures and changes in device outcome measures in PAH patients using the new Breelib nebulizer in a real…
- Trial name
- VENTASTEP (NCT03293407)
- Testing
- Iloprost (Ventavis, BAYQ6256), Breelib nebulizer
- Where
- Germany
- Volunteers
- 31 people
- Sponsor
- Bayer
Cardiovascular Disease
Evaluation of a New Thermostable Formulation of FLOLAN in Japanese Subjects
This study is a Phase IV, open-label, single-arm study to assess the safety and the necessity of dose adjustment after switching to FLOLAN injection prepared with the reformulated diluent in Japanese patients with PAH who are…
- Trial name
- NCT02705807
- Testing
- FLOLAN injection with currently marketed diluent, FLOLAN injection with reformulated diluent
- Where
- Japan
- Volunteers
- 10 people
- Sponsor
- GlaxoSmithKline
Pulmonary Arterial Hypertension
Open Label Access Study Of Sildenafil In Adult Patients With Pulmonary Arterial Hypertension Completing A1481244 Study
In an earlier study, sildenafil citrate administered to patients of PAH led to improvement in pulmonary arterial pressure, cardiac output, quality of life, and other parameters as compared to placebo.
- Trial name
- UK 92480 (NCT00878943)
- Testing
- Sildenafil citrate
- Where
- 5 sites in India
- Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Pulmonary Arterial Hypertension
An Open-Label Extension of BPS-MR-PAH-201 in Pulmonary Arterial Hypertension (PAH) Patients
This is an open-label extension study for patients who participated in the BPS-MR-PAH-201 study.
- Trial name
- NCT00792571
- Testing
- Beraprost Sodium Modified Release
- Where
- 6 sites in United States, Belgium and 1 more
- Volunteers
- 18 people
- Sponsor
- Lung Biotechnology PBC
Chronic Thromboembolic Pulmonary Hypertension, Pulmonary Arterial Hypertension
DataBase of pulmoNary hyPertesion in PoLish Population - BNP-PL
The BNP-PL is a multicenter, observational study in which patients are prospectively followed in order to investigate clinical course and management of pulmonary hypertension in Poland.
- Trial name
- BNP-PL (NCT03959748)
- Where
- Poland
- Volunteers
- 3,000 people
- Sponsor
- Polish Cardiology Association
Adenovirus, Anesthesia
Pharmacokinetics of Understudied Drugs Administered to Children Per Standard of Care
Understudied drugs will be administered to children per standard of care as prescribed by their treating caregiver and only biological sample collection during the time of drug administration will be involved.
- Conditions
- Adenovirus, Anesthesia, Anxiety, Anxiolysis
- Trial name
- PTN_POPS (NCT01431326)
- Testing
- The POPS study is collecting PK data on children prescribed the following drugs of interest per standard of care:
- Where
- 52 sites in United States, Canada and 3 more
- Volunteers
- 3,520 people
- Sponsor
- Daniel Benjamin
Intrahepatic Cholangiocarcinoma (Icc)
HAIC Plus Systemic Chemotherapy, Lenvatinib and Toripalimab in Advanced ICC
Prognosis for unresectable intrahepatic cholangiocarcinoma (ICC) remains poor. Treatment combination known as Gemox (systemic chemotherapy of gemcitabine and oxaliplatin), along with lenvatinib and toripalimab, has shown favor…
- Trial name
- NCT07304388
- Testing
- hepatic arterial infusion chemotherapy (HAIC), Chemotherapy
- Where
- China
- Volunteers
- 96 people
- Sponsor
- Sun Yat-sen University
Pulmonary Arterial Hypertension
A Study of Sotatercept (MK-7962) in Japanese Children With Pulmonary Arterial Hypertension (PAH) (MK-7962-032)
The goal of this study is to learn about the safety of sotatercept and how well Japanese children tolerate it, when taken along with standard (usual) pulmonary arterial hypertension (PAH) treatment.
- Trial name
- NCT07646860
- Testing
- Sotatercept
- Where
- 3 sites in Japan
- Volunteers
- 6 people
- Sponsor
- Merck Sharp & Dohme LLC
Pulmonary Arterial Hypertension
Study of Add-on Ambrisentan Therapy to Background Phosphodiesterase Type-5 Inhibitor (PDE5i) Therapy in Pulmonary Arterial Hypertension (ATHENA-1)
To evaluate the change from baseline in pulmonary vascular resistance (PVR), and other hemodynamic parameters, following the addition of ambrisentan to background phosphodiesterase type-5 inhibitor (PDE-5i) therapy in subjects…
- Trial name
- ATHENA-1 (NCT00617305)
- Testing
- Ambrisentan, Sildenafil, Tadalafil
- Where
- 30 sites in United States
- Volunteers
- 38 people
- Sponsor
- Gilead Sciences
Pediatric Pulmonary Hypertension
Actigraphy in Pediatric Pulmonary Hypertension
Physical activity is an important factor in understanding how diseases can affect a child. Decreases in physical activity are sometimes the first thing that happens before a child is diagnosed with a disease.
- Trial name
- NCT02909608
- Testing
- No interventions / observations only
- Where
- 2 sites in United States
- Volunteers
- 116 people, healthy volunteers welcome
- Sponsor
- University of Colorado, Denver
Pulmonary Arterial Hypertension (PAH), Lung Fibrosis Interstitial
PROOF OF CONCEPT STUDY ON THE EFFICACY OF INHALATORY TARGETED IMATINIB NANOFORMULATIONS IN PULMONARY HYPERTENSION AND POST-INFLAMMATORY FIBROSIS.
The PROMPTLY study is a proof-of-concept research project evaluating the efficacy of XHALIP, an innovative inhalable formulation of Imatinib, in treating pulmonary arterial hypertension (PAH) and post-inflammatory fibrosing lung…
- Trial name
- PROMPTLY (NCT06917196)
- Where
- Italy
- Volunteers
- 16 people
- Sponsor
- Fondazione IRCCS Policlinico San Matteo di Pavia
Aortic Valve Stenosis, Pulmonary Hypertension
Prognostic Impact of the Evolution of PAH 3 Months After TAVI (HTP-TAVI)
Aortic stenosis (AS) is the most frequent valvulopathy in Western countries. The prevalence of AS is constantly increasing due to the aging of the population.
- Trial name
- HTP-TAVI (NCT04008550)
- Testing
- Right Heart Catheterization
- Where
- France
- Volunteers
- 101 people
- Sponsor
- University Hospital, Rouen
Pulmonary Arterial Hypertension, Pulmonary Hypertension
Treatment of Pulmonary Arterial Hypertension Using the Aria CV Pulmonary Hypertension System
This prospective study is a multi-center early feasibility study assessing the safety and performance of the Aria CV Pulmonary Hypertension System in patients with pulmonary hypertension and right heart dysfunction.
- Conditions
- Pulmonary Arterial Hypertension, Pulmonary Hypertension, Right Heart Dysfunction
- Trial name
- ASPIRE PH (NCT04555161)
- Testing
- Aria CV Pulmonary Hypertension System
- Where
- 12 sites in United States
- Volunteers
- 30 people
- Sponsor
- Aria CV, Inc
Pulmonary Arterial Hypertension
A Prospective Non-interventional Observational Study to Observe Long-term Treatment and Outcomes in Pulmonary Arterial Hypertension (PAH) Patients
The goal of this observational study is to learn about the long-term development and outcomes of different treatment patterns of patients who initially participated in the TripleTRE study.
- Trial name
- TripleTRE-NIS (NCT06445673)
- Where
- 18 sites in Austria, Czechia and 7 more
- Volunteers
- 110 people
- Sponsor
- AOP Orphan Pharmaceuticals AG